- Home
- PODC vs SER Comparison
PODC vs SER Comparison
Compare PODC & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- SER
- Stock Information
- Founded
- PODC 2013
- SER 2017
- Country
- PODC United States
- SER United States
- Employees
- PODC N/A
- SER N/A
- Industry
- PODC
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- SER Health Care
- Exchange
- PODC Nasdaq
- SER Nasdaq
- Market Cap
- PODC 47.8M
- SER 55.2M
- IPO Year
- PODC N/A
- SER 2018
- Fundamental
- Price
- PODC $2.31
- SER $3.96
- Analyst Decision
- PODC
- SER Strong Buy
- Analyst Count
- PODC 0
- SER 2
- Target Price
- PODC N/A
- SER $13.00
- AVG Volume (30 Days)
- PODC 56.7K
- SER 28.8K
- Earning Date
- PODC 11-11-2025
- SER 11-11-2025
- Dividend Yield
- PODC N/A
- SER N/A
- EPS Growth
- PODC N/A
- SER N/A
- EPS
- PODC N/A
- SER N/A
- Revenue
- PODC $53,954,000.00
- SER $130,000.00
- Revenue This Year
- PODC $17.39
- SER $134.46
- Revenue Next Year
- PODC $19.94
- SER N/A
- P/E Ratio
- PODC N/A
- SER N/A
- Revenue Growth
- PODC 17.74
- SER N/A
- 52 Week Low
- PODC $1.28
- SER $3.70
- 52 Week High
- PODC $2.94
- SER $7.92
- Technical
- Relative Strength Index (RSI)
- PODC 70.32
- SER 29.95
- Support Level
- PODC $2.08
- SER $4.60
- Resistance Level
- PODC $2.29
- SER $5.00
- Average True Range (ATR)
- PODC 0.16
- SER 0.29
- MACD
- PODC 0.03
- SER -0.11
- Stochastic Oscillator
- PODC 93.55
- SER 16.40
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.